Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceu
'/>"/>

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. ... research and development of compounds to safely regress ... today announces that its partner, CardioNova, has accomplished ... clinical trial with AtheroNova,s lead compound, AHRO-001.  This ... the AHRO-001 Phase 1 safety trial completed in ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... from the U.S. Environmental Protection Agency (EPA). This ... in developmental toxicity models, including tests designed to ... formation and the formation of connections between neurons ... of neurodifferentiation and synapse formation by environmental pollutants ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... Preclinical Research at Upcoming Conferences, CALGARY, Sept. ... ONCY) today announced the participation of five of ... conferences,through November 15, 2008 covering clinical trial results ... time for Oncolytics as we begin to share ...
... Surgeons with No-Touch,Surgical Tool For Precision Brain ... 22 OmniGuide, Inc., announced,today the introduction ... flexible,CO2 laser scalpel for neurosurgery. The BeamPath ... microsurgical tool for various central,nervous system (CNS) ...
... their health, yet up to ... elevated risk for cardiovascular events, yet 20 percent, of those have not spoken ... ... A new survey of men and,women age 40 and older in the United ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 2OmniGuide Introduces The BeamPath Neuro(TM): A CO2 Laser Fiber for Brain And Spine Surgery 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 4Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 5Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 6Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 7
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
(Date:7/30/2014)... the first high-resolution map of the carbon stocks ... Per. The new and improved methodology used to ... future market-based carbon economies. The new carbon ... and it provides the critical input to studies ... use, and enforcement purposes. The technique includes the ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... of branching - wild varieties of the plant Arabidopsis ... of this small mustard plant, a favorite of many ... strains from the polar circle or the subtropics, from ... first time by research teams from Tübingen, Germany, and ...
... discovered one way the p53 gene does what it's known ... in the June 8 issue of Molecular Cell. , ... a microRNA called miR-34a that participates in p53's uncanny ability ... genes in their nuclei. MicroRNAs are small chains of ribonucleic ...
... Aspirin didn’t pan out. Neither did two other potential ... desert shrub is now a front- runner in ongoing ... to inhibit inflammation, cancer and other destructive processes, can ... the annual meeting of the American Aging Association, University ...
Cached Biology News:One species, many genomes 2One species, many genomes 3Common cancer gene sends death order to tiny killer 2Agent slows aging in mice 2
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
... Localization in Early Drug Development with Imaging ... essential drug compound localization data in early ... imaging mass spectrometry service maps unlabeled ... images so you can localize drugs and ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: